Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers

Resistance to endocrine treatments and CDK4/6 inhibitors is considered a near-inevitability in most patients with estrogen receptor positive breast cancers (ER + BC). By genomic and metabolomics analyses of patients’ tumours, metastasis-derived patient-derived xenografts (PDX) and isogenic cell line...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Botty, Rania, Morriset, Ludivine, Montaudon, Elodie, Tariq, Zakia, Schnitzler, Anne, Bacci, Marina, Lorito, Nicla, Sourd, Laura, Huguet, Léa, Dahmani, Ahmed, Painsec, Pierre, Derrien, Heloise, Vacher, Sophie, Masliah-Planchon, Julien, Raynal, Virginie, Baulande, Sylvain, Larcher, Thibaut, Vincent-Salomon, Anne, Dutertre, Guillaume, Cottu, Paul, Gentric, Géraldine, Mechta-Grigoriou, Fatima, Hutton, Scott, Driouch, Keltouma, Bièche, Ivan, Morandi, Andrea, Marangoni, Elisabetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349040/
https://www.ncbi.nlm.nih.gov/pubmed/37452026
http://dx.doi.org/10.1038/s41467-023-40022-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349040/
https://www.ncbi.nlm.nih.gov/pubmed/37452026
http://dx.doi.org/10.1038/s41467-023-40022-5

Ejemplares similares